The Finsbury Worldwide Pharmaceutical trust has cut its gearing by almost half over the six months t...
The Finsbury Worldwide Pharmaceutical trust has cut its gearing by almost half over the six months to 30 September, reducing the drawdown on its loan facility from £50m to £27m. The the trust's interim results show NAV per share declined from 557.6p to 342.6p over the review period. Chairman Sir Stuart Burgess said revenue generated from the company's investments continues to be modest and no interim dividend is being declared. He said the board will declare dividends only to the extent required to maintain investment trust status.
Putting the tech into protection
Square Mile’s series of informal interviews
Fallout from Haywood suspension
Launching later in 2019
£80bn funds under calculation